Excretion of excess sugar into the urinary tract due to SGLT2i intake raised concerns about the risk of urinary tract infections (UTIs); therefore, this drug was discontinued after hospitalization, while DM was controlled via insulin therapy. This evidence concerns the gene INS and urinary tract infection.